Idarubicin

Liver Cancer

Second Affiliated Hospital of Guangzhou Medical UniversitySmall moleculePhase 3Active

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 65/ 100
Competitive Position: 65/ 100

Competitive context

110 Active assets in the Liver Cancer cohort.

Asset / Sponsor	Phase	Rating
Dexmedetomidine Uppsala University Hospital	Phase 4	BBB
DOXORUBICIN Shanghai Zhongshan Hospital	Phase 4	BB
OXALIPLATIN Sun Yat-sen University	Phase 3	BB
Hepatitis B Virus Vaccine Eunice Dube	Phase 4	BB
SUFENTANYL The Second Affiliated Hospital of Chongqing Medical University	Phase 4	BB

View all 50 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative · Phase 4

81 / 100

acute myeloid leukemia with 11q23 abnormalitiesDormant

BBB

Indicative · Phase 2

76 / 100

adult acute lymphoblastic leukemiaActive

BBB

Indicative · Phase 4

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.